​1.Ligstroside aglycone against metastatic breast cancer

In the study of Busnena , ligstroside aglycone showed the best antimigratory activity in experiments performed in highly metastatic human breast cancer cells. Due to its particular chemical structure, it inhibits the activity of a specific protein, the c-MET protein, associated with the development of malignant tumor.​

https://www.ncbi.nlm.nih.gov/pubmed/23403296

 

2. The effect of Ligstroside aglycone on breast cancer

Menendez in their study explored the ability of ligstroside aglycone to modulate HER2 tyrosine kinase receptor-induced, which is present in large amounts in breast cancer cells and causes their uncontrolled proliferation. Ligstroside aglycone was one of the most active inhibitors of HER2 expression in cells, with a reduction 63%, even in very small doses and eventually the cancer cells were led to programmed cell death. These findings provide an excellent and safe platform for the design of new anti-breast cancer drugs.

https://www.ncbi.nlm.nih.gov/pubmed/19094209